Prescribing direct-acting oral anticoagulants - Mind the evidence gap.
Adeyeye, Elizabeth Maniero, Carmela Magavern, Emma F McGettigan, Patricia
Adeyeye, Elizabeth
Maniero, Carmela
Magavern, Emma F
McGettigan, Patricia
Citations
Altmetric:
Affiliation
Barts Health NHS Trust; Queen Mary University of London; Sandwell and West Birmingham NHS Trust; University of Birmingham
Other Contributors
Publication date
2022-07-13
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Direct-acting oral anticoagulants (DOACs) are licensed for the prevention of thromboembolism in non-valvular atrial fibrillation, amongst other indications. Prescribers use information derived from the summary of product characteristics which is based on the key trials supporting the DOAC's market authorisation. However, prescribers may not be aware of the limitations within these trials regarding underrepresentation of patient populations commonly encountered in clinical practice and how this may adversely impact them. This review highlights the gaps in the licensing evidence using four clinical vignettes that explore prescribing challenges in older adults, female patients, patients with obesity and patients from non-Europid ethnic backgrounds.
Citation
Adeyeye E, Maniero C, Magavern EF, Ferner RE, McGettigan P. Prescribing direct-acting oral anticoagulants - Mind the evidence gap. Br J Clin Pharmacol. 2022 Nov;88(11):4724-4731. doi: 10.1111/bcp.15450
Type
Article